Comorbidity in alopecia areata
INESSA SERBINA
Scientific consultant, TRICHOLOGY INSTITUTE ®
Сербина, И. М. Коморбидность при гнездной алопеции // ДЕРМАТОЛОГІЯ ТА ВЕНЕРОЛОГІЯ —№ 2 — 2018 стр. 67-70
Introduction
Comorbid diseases are an everyday clinical reality today, which makes it necessary to analyse them, study the causes of their occurrence and treat them effectively [3, 9]. The concept of comorbidity, the simultaneous involvement of two or more organs or body systems, has received fairly wide coverage in the literature of recent years. “Polypathology” and “multimorbidity” or “polymorbidity” are used as synonyms of “comorbidity”, although the discussion about different interpretations of these terms continues [1, 2].
Clinical studies have shown that the high prevalence of co-occurring diseases cannot be fully explained by their mathematical addition alone. Comorbidity may follow the pattern of syntropy (simultaneous involvement of organs under the influence of similar aetiological and pathogenetic factors, the diseases being, as it were, “drawn” to each other) or of interference (the occurrence of one disease under the influence of another) [3, 9]. Factors assumed to influence the development of comorbidity are genetic predisposition, involutional and systemic metabolic changes, chronic infection, inflammation, iatrogenesis, social status and ecology [1, 2].
It is now established that associations of diseases at the level of clinical phenotypes have a molecular genetic basis: shared genes and overlapping metabolic pathways. The combination of pathologies may rest on the phenomenon of gene pleiotropy, expressed in the ability of one gene to influence several phenotypic traits. Typical nonspecific pathophysiological mechanisms (impaired membrane function, oxidative stress, endothelial dysfunction, etc.) also play an important role in the development of comorbidity [1, 2, 3, 13].
Alopecia areata (AA) is a genetically determined chronic inflammatory disease of the hair follicles. It is unpredictable in character, may affect the scalp and/or hair in other areas, and may present as isolated patches of non-scarring hair loss or as extensive, rapid total hair loss. Recently the number of patients with AA has been growing, and there is a clear trend towards an increase in severe and torpid forms [4, 15]. The chronic relapsing course of the dermatosis leads to emotional disturbance and social maladaptation, and substantially worsens the quality of life of the patient and relatives [5, 10].>
To this day AA remains terra incognita. The latest discoveries in the study of AA shed light on its genetic and immune pathogenesis. The autoimmune scenario of AA development is currently the best explanation of the data obtained in clinical studies. The mechanisms of AA development are based on cell-mediated local immune reactions associated with T lymphocytes (CD8+ and CD4+) and changes in the cytokine profile, determined by genetic factors and exogenous triggers, which leads to the formation of nonspecific autoimmune inflammation against a background of breakdown of the immune tolerance of the hair follicle. Genetic studies and analysis of human gene expression have shown the significance of disturbances of the NKGD-activating ligand and the natural cytotoxicity receptor NKG2D, and of the JAK-STAT signalling system, for the development of AA [3, 4, 11, 12, 13].The problem of comorbid conditions in patients with AA is relevant to modern practical dermatology, since the influence of concomitant diseases on the course and treatment outcomes of the disease remains little studied. Individual studies show that AA is associated with atopic dermatitis, mental disorders and autoimmune diseases. At the same time, there are data showing no correlation with these conditions in patients with AA [8, 9, 14].
The controversy over concomitant pathology in AA motivates further research in this direction. In this connection the aim of the work was defined: to identify the most significant and frequent comorbid conditions in patients with AA.
Materials and methods
We observed 110 patients diagnosed with AA (44 men, 66 women) aged 18–60 years (mean age 27.0±0.5 years). Various clinical forms of AA were identified in the patients examined: patchy, ophiasis, inverse ophiasis, multifocal, unspecified (incognita, diffuse), total and universal alopecia.
A patient was included in the study if his or her condition (history, clinical data) met the criteria and features defining the patient model. The diagnosis was made on the basis of the clinical picture of the disease and the findings of instrumental diagnostic examination: in the presence of single or multiple patches of hair loss on the scalp, or complete absence of hair on the head and/or other areas of the skin.
The severity of the disease was assessed according to the SBN scale, recommended by an international expert group for assessing the extent of hair loss and nail involvement in AA. The degree of hair loss was assessed using the criteria for measuring AA severity on the scalp, S0–S5, proposed by Olsen et Canfield [4]. Statistical analysis of the study results was performed using the Statistica 8.0 software package.
By clinical forms, taking the severity measurement criteria into account, patients with AA were distributed as follows:
• mild severity (less than 25%): S1 – 44 patients;
• moderate severity – clinical forms in the form of multifocal alopecia, including ophiasis and diffuse: S2–S4a – 38 people (S2 (25–49% hair loss) – 14, S3 (50–74% hair loss) – 12, S4a (75–95% hair loss) – 12);
• severe – multifocal form (subtotal; hair loss 96–99%): S4b – 8;
• total (100% absence of hair on the scalp) and universal alopecia (100% absence of hair on the head, face and body): S5 – 20 people.
Results and discussion
The onset of AA varied across a wide age range, from 5 to 45 years. The mean age at onset of the pathological process was 19.2±5.4 years. In 30 patients (27.2%) the first episode of the disease occurred before the age of 8, in 4 of them before the age of 3; in 28 (25.4%) at 9–14 years; in 10 (9%) at 15–17 years; in 42 (38.2%) at 18 years and older.
32.7% of patients named stress as a provoking factor of AA. A link between the onset of the disease and atopic and autoimmune diseases (autoimmune thyroiditis, vitiligo, atopic dermatitis) was noted by 16.3% of patients. 9% of patients linked the onset of alopecia to endocrine changes (childbirth, menopause), 8.2% to vaccination (influenza vaccine, hepatitis B vaccination). 5.5% of patients named infectious diseases (acute respiratory illness, pneumonia, etc.) as the cause of AA. 28.3% of patients did not link the cause of the disease to anything.
In 59 (53.6%) patients with AA an association with various diseases was found. Manifestations of atopy, including atopic dermatitis, allergic rhinitis and bronchial asthma, prevailed in patients with AA and amounted to 30.2%, while contact dermatitis and eczema were diagnosed in 11.4%. Hyperlipidaemia and hypertension were observed in 10.2% and 8.5% of patients respectively. Psychological disorders of the type of anxiety disorder, depression and sleep disturbance were found in 26.3% of patients. Anaemia and iron-deficiency states occurred in 10.6% of patients. Vitamin D deficiency was diagnosed in 25.4% of cases; a link with autoimmune diseases was noted in 53.3% of patients with concomitant pathology: thyroid disease in the form of autoimmune Hashimoto thyroiditis (20.4%), diabetes mellitus (8.4%), systemic lupus erythematosus and scleroderma (4.2%), rheumatoid arthritis (3.4%), vitiligo (10.2%), psoriasis (6.7%). Diseases of the gastrointestinal tract (chronic gastritis and peptic ulcer of the stomach and duodenum, coeliac disease) were observed in 7.5% of patients, ENT diseases (sinusitis) in 4.2%. Endocrine disorders of the type of hypo- or hyperthyroidism were recorded in 11.8% of patients. Hyperandrogenism was found in 6.7% of women.
Patients with concomitant diseases had more severe forms of AA compared with patients without somatic pathology. Correlation analysis showed a link between individual comorbid conditions and the severity of AA. Thus, a positive correlation was found between atopy, psychological disorders and severe AA (р<0.01). The prevalence of comorbidity was 28% in patients aged 18–44 years and 52% in those aged 45–60 years.
The data obtained demonstrate a high frequency of AA co-occurring with various diseases. Diseases associated with AA precede the dermatosis or arise against the background of an already developed dermatosis. Concomitant diseases may influence the initiation, character and course of the skin process. In AA, as in any chronic inflammatory dermatosis, favourable ground is created for the appearance of other lesions. The combination of pathologies may be due to a single, albeit presumed, cause or to pathogenetic proximity (impaired immune response), yet it is not always possible to trace common features in the mechanism of development of the diseases. In light of modern views on this problem, one can speak of multifactorial diseases, or comorbidity [1, 2, 3, 8].
Our results are consistent with previous data on the high prevalence of other immune-mediated diseases among patients with AA. We found high associations with atopy in AA. The incidence of atopy in patients with AA is reported to range from 11 to 38.2%. The results of molecular research suggested the presence of filaggrin mutations in these conditions, affecting the integrity of the epidermal barrier. Data have been presented linking atopy with an increased risk of AA and a severe course of the disease [5, 7, 14]. Our study confirms these preliminary conclusions.
Patients with AA are prone to an increased frequency of autoimmune pathology, which is explained by the commonality of the immunological mechanisms of development of these diseases. An autoimmune reaction of the thyroid gland has been described in other sources as the main association with AA, with a prevalence from 8% to 28%. A significant rise in the level of autoantibodies to cellular components of the thyroid gland has been found in patients with AA, which gave grounds to recommend testing all patients with AA for thyroid autoantibodies and thyroid dysfunction, for their timely detection and adequate treatment. However, the opinion has been expressed that the presence of thyroid autoantibodies has no clinical correlation with the severity of AA [5, 6, 7, 9].
AA reduces patients' quality of life. We found a high frequency of mental comorbid pathology among our patients with AA. The “disfiguring effect” of the dermatosis is regarded as a factor provoking a whole spectrum of “secondary” mental disorders. We found that more pronounced disturbances are associated with young age, when social adaptation and job seeking are so important. A relationship between AA and suicide attempts has been reported, which vividly testifies to the underestimated importance of the psychosocial aspect in the presence of hair loss [14, 15]. However, evidence for the role of stress in the initiation or aggravation of this disease is actually still lacking. It is also disputed whether AA should be considered a psychosomatic disease. Our study demonstrated the dependence of AA severity on the state of the psychological status.
Immunoinflammatory and metabolic disorders are able to alter homeostasis and may contribute to the development of such conditions as deficiency states, endocrine disorders, hyperlipidaemia, hypertension and diseases of the digestive tract, which we found in a small number of patients [5, 14, 15]. On the one hand, they may be triggers for the onset of AA; on the other, they may develop against the background of AA. Further research in this direction will help clarify the course of such comorbid conditions, which will be of clinical significance for understanding the patterns of development of alopecia and determining optimal therapeutic approaches.
Conclusions
Thus, interest in comorbid conditions in AA is due to their influence on the course and prognosis of the disease itself, the choice of treatment tactics and the quality of life of patients. Concomitant diseases may appear before the development of AA, during exacerbation or during remission. The varying degree of “interaction” between AA and concomitant diseases should be taken into account. Comorbidity cannot be understood as a sum or the result of adding up some number of diseases and an automatic worsening of the patient's condition; behind it there probably stand those patterns of formation of human pathology and that essence of disease which have yet to be studied and understood.
1. Макулбекова С.К. Полиморбидность у больных и их роль в диагностике и лечении (литературный обзор). Вестник КРСУ. 2015. Т. 15, No 11. С. 100–102.
2. Наумова Л.А., Осипова О.Н. Коморбидность: механизмы патогенеза, клиническое значение. Современные проблемы науки и образования. 2016. No 5.
3. Поровский Я.В., Тетенев Ф.Ф. Коморбидность во врачебной практике. Сибирское медицинское обозрение. 2015. No 4. С. 5–10.
4. Практическая дерматология: уч. пособие для врачей-интернов и врачей-слушателей заведений (факультетов) последипломного образования / Л. А. Болотная [и др.]; под общ. ред. Л. А. Болотной. Х. : С.А.М., 2015. 278 с.
5. Autoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States / K.P. Huang, S. Mullangi, Y. Guo, A.A. Qureshi. JAMA Dermatol. 2013. Vol. 149, Iss. 7. P. 789–794.
6. Baars M.P., Greebe R.J., Pop V.J. High prevalence of thyroid peroxidase antibodies in patients with alopecia areata. J Eur Acad Dermatol Venereol. 2013. Vol. 27, Iss. 1. P. e137–e139.
7. Barahmani N., Schabath M.B., Duvic M. National Alopecia Areata Registry. History of atopy or autoimmunity increases risk of alopecia areata. J Am Acad Dermatol. 2009. Vol. 61, Iss. 4. P. 581–591.
8. Comorbidities in patients with alopecia areata / R.Z. Conic, R. Miller, M. Piliang et al. J Am Acad Dermatol. 2017. Vol. 76, Iss. 4. P. 755–757.
9. Comorbidity and multimorbidity in the medical practice: A literature review / L. Collaku, M. Resuli, I. Gjermeni, M. Tase. Alban Med J. 2017. Vol. 4. P. 55–59.
10. Comorbidity profiles among patients with alopecia areata: the importance of onset age, a nationwide population-based study / S.Y. Chu, Y.J. Chen, W.C. Tseng et al. J Am Acad Dermatol. 2011. Vol. 65, Iss. 5. P. 949–956.
11. Craiglow B.G., Liu L., King B. Tofacitinib for the treatment of alopecia areata and variants in adolescents. J Am Acad Dermatol. 2017. Vol. 76. P. 29–32.
12. Genetic basis of alopecia areata: a roadmap for translational research / A. Jabbari, L. Petukhova, R.M. Cabral et al.. Dermatol Clin. 2013. Vol. 31, Iss. 1. P. 109–117.
13. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci / R.C. Betz, L. Petukhova, S. Ripke et al. Nat Commun. 2015. Vol. 6. P. 5966.
14. Villasante Fricke A.C., Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015. Vol. 24, Iss. 8. P. 397–403.
15. Wang E., Christiano A. The Changing Landscape of Alopecia Areata: The Translational Landscape. Advances in Therapy. 2017. Vol. 34, Iss. 7. P. 1586–1593.
References
1. Makulbekova SK. Polimorbidnost u bolnykh i ikh rol v diagnostike i lechenii (literaturnyy obzor) (Polymorbidity in patients and their role in diagnosis and treatment (literary review). Vestnik KRSU. 2015;15(11):100–102.
2. Naumova LA, Osipova ON. Komorbidnost: mekhanizmy patogeneza. klinicheskoye znacheniye (Comorbidity: mechanisms of pathogenesis, clinical significance). Sovremennyye problemy nauki i obrazovaniya. 2016;5.
3. Porovskiy YaV, Tetenev FF. Komorbidnost vo vrachebnoy praktike (Comorbidity in medical practice). Sibirskoye meditsinskoye obozreniye. 2015;4:5–10.
4. Bolotnaya LA, editor. Prakticheskaya dermatologiya: uch. posobiye dlya vrachey-internov i vrachey-slushateley zavedeniy (fakultetov) poslediplomnogo obrazovaniya (Practical dermatology: the ed. manual for interns and doctors-listeners of institutions (faculties) of post-graduate education). Kh.: S.A.M; 2015. 278 s.
5. Huang KP, Mullangi S, Guo Y, Qureshi AA. Autoimmune, atopic, and mental health co- morbid conditions associated with alopecia areata in the United States. JAMA Dermatol. 2013;149(7):789–794.
6. Baars MP, Greebe RJ, Pop VJ. High prevalence of thyroid peroxidase antibodies in patients with alopecia areata. J Eur Acad Dermatol Venereol. 2013;27(1):e137–e139.
7. Barahmani N, Schabath MB, Duvic M. History of atopy or autoimmunity increases risk of alopecia areata. J Am Acad Dermatol. 2009;61(4):581–591.
8. Conic RZ, Miller R, Piliang M, et al. Comorbidities in patients with alopecia areata. J Am Acad Dermatol. 2017;76(4):755–757.
9. Collaku L, Resuli M, Gjermeni I, Tase M. Comorbidity and multimorbidity in the medical practice: A literature review. Alban Med J. 2017;(4):55–59.
10. Chu SY, Chen YJ, Tseng WC, et al. Comorbidity profiles among patients with alopecia areata: the importance of onset age, a nationwide population-based study. J Am Acad Dermatol. 2011;65(5):949–956. 1
1. Craiglow BG, Liu L, King B. Tofacitinib for the treatment of alopecia areata and variants in adolescents. J Am Acad Dermatol. 2017;76:29–32.
12. Jabbari A, Petukhova L, Cabral RM, et al. Genetic basis of alopecia areata: a roadmap for translational research. Dermatol Clin. 2013;31(1):109–117.
13. Betz RC, Petukhova L, Ripke S, et al. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat Commun. 2015;6:5966.
14. Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;24(8):397–403.
15. Wang E, Christiano A. The Changing Landscape of Alopecia Areata: The Translational Landscape. Advances in Therapy. 2017;34(7):1586–1593.